

## New indicator for discordance between patient-reported and traditional disease activity outcomes in patients with early Rheumatoid Arthritis

Pazmino, Sofia; Lovik, Anikó; Boonen, Annelies; De Cock, Diederik; Stouten, Veerle; Joly, Johan; Doumen, Michaël; Bertrand, Delphine; Westhovens, René; Verschueren, Patrick

*Published in:*  
Rheumatology (Oxford, England)

*DOI:*  
[10.1093/rheumatology/keac213](https://doi.org/10.1093/rheumatology/keac213)

*Publication date:*  
2023

*License:*  
Unspecified

*Document Version:*  
Accepted author manuscript

[Link to publication](#)

### *Citation for published version (APA):*

Pazmino, S., Lovik, A., Boonen, A., De Cock, D., Stouten, V., Joly, J., Doumen, M., Bertrand, D., Westhovens, R., & Verschueren, P. (2023). New indicator for discordance between patient-reported and traditional disease activity outcomes in patients with early Rheumatoid Arthritis. *Rheumatology (Oxford, England)*, *62*(1), 108-115. <https://doi.org/10.1093/rheumatology/keac213>

### **Copyright**

No part of this publication may be reproduced or transmitted in any form, without the prior written permission of the author(s) or other rights holders to whom publication rights have been transferred, unless permitted by a license attached to the publication (a Creative Commons license or other), or unless exceptions to copyright law apply.

### **Take down policy**

If you believe that this document infringes your copyright or other rights, please contact [openaccess@vub.be](mailto:openaccess@vub.be), with details of the nature of the infringement. We will investigate the claim and if justified, we will take the appropriate steps.



1  
2  
3 **New indicator for discordance between patient-reported and traditional disease activity**  
4  
5 **outcomes in patients with early Rheumatoid Arthritis**  
6  
7

8  
9 Sofia Pazmino <sup>1</sup>, Anikó Lovik<sup>2</sup>, Annelies Boonen<sup>3,4</sup>, Diederik De Cock<sup>1,5</sup>, Veerle Stouten<sup>1</sup>, Johan  
10 Joly<sup>6</sup>, Michaël Doumen<sup>1</sup>, Delphine Bertrand<sup>1</sup>, René Westhovens<sup>1,6</sup>, Patrick Verschueren<sup>1,6</sup>  
11  
12

13  
14 <sup>1</sup>Department of Development and Regeneration, Skeletal Biology and Engineering Research  
15 Centre, KU Leuven, Leuven, Belgium  
16  
17

18  
19  
20 <sup>2</sup>I-BioStat, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium  
21

22  
23 <sup>3</sup>Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical  
24 Centre, Maastricht, The Netherlands  
25  
26

27  
28 <sup>4</sup>Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The  
29 Netherlands  
30  
31

32  
33  
34 <sup>5</sup>Laboratory of Clinical and Experimental Endocrinology, University of Leuven, Leuven, Belgium.  
35

36  
37 <sup>6</sup>Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium  
38

39  
40 **Corresponding author:** Sofia Pazmino. Mailing address: Division of Rheumatology, University  
41 Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium.  
42  
43

44  
45  
46 ORCID iD <https://orcid.org/0000-0001-8579-6914>  
47

48  
49 E-mail: [sofia.pazmino@kuleuven.be](mailto:sofia.pazmino@kuleuven.be); Tel: +32-16-342541; Fax: +32-16-342543  
50  
51

**KEY MESSAGES**

- Including pain, fatigue and functionality when assessing early RA patients broadens evaluation of disease impact.
- Novel factor-score detects unmet needs to be used for predicting future disease control and quality-of-life.
- The earlier detection of unmet needs could signal the need for timely interdisciplinary interventions.

**KEYWORDS:**

Early rheumatoid arthritis, patient-reported outcomes, discordance, unmet needs, factor scores, measurement instrument

**ABSTRACT**

**Objective:** To unravel disease impact in early Rheumatoid Arthritis (RA) by separately quantifying patient-reported (PRF), clinical (CF) and laboratory (LF) factors. We propose a new indicator, the discordance score (DS), for early identification and prediction of patient's unmet needs and of future achievement of sustained remission (SR) and RA-related quality of life (QoL).

**Methods:** Factor-scores obtained by factor analysis in the CareRA trial, allowed to compute DS, reflecting the difference between PRF and the mean of CF and LF. Improvement from baseline to week 104 (%) and area-under-the-curve (AUC) across time points per factor-score were calculated and compared between patients achieving/not achieving sustained (week 16-104) remission (DAS28CRP<2.6) with ANOVA. Logistic and linear regressions were used to predict SR based on previous factor and discordance scores, and QoL at year 1 and 2 based on DS at week 16.

**Results:** PRF, CF and LF scores improved rapidly within 8 weeks. PRF improved 57%, CF 90% and LF 27%, in those achieving SR, compared to 32% (PRF:p=0.13), 77% (CF:p<0.001) and 9% (LF:p=0.36) in patients not achieving SR. Patients achieving SR had an AUC of 15.7, 3.4 and 4.8 for PRF, CF and LF, respectively, compared to 33.2, 10.1, and 7.2 in participants not achieving SR (p<0.001 for all). Early discordance was associated with later factor scores, QoL, and self-efficacy.

**Conclusions:** All factor scores improved rapidly, especially in patients achieving SR. Patient-reported burden improved less. Discordance scores could help predicting the need for additional non-pharmacological interventions to achieve SR and decrease disease impact.

## INTRODUCTION

The primary clinical manifestation of Rheumatoid Arthritis (RA) is inflammation of the peripheral joints resulting in swelling, stiffness and pain.(1) However, more constitutional symptoms such as fatigue, restricted ability to work, and impact on other aspects of health-related quality of life (QoL) can be present.(2) Treating early to a target of remission or at least low disease activity is highly advocated.(3) This treatment strategy aims to maximise the long-term health-related quality of life through control of symptoms, prevention of structural damage, normalisation of function and social participation.(4) However, a clear definition of the treatment target is paramount to this strategy and should be stringent enough to seek “the best possible control of inflammation” while avoiding overtreatment.(5)

Specific instruments are used to measure the target of remission or low disease activity.(3) For example, the ACR/EULAR Boolean remission criterion is stringent, requiring swollen/tender joint counts (SJC/TJC) to be below or equal to ( $\leq$ ) 1, C-reactive protein (CRP)  $\leq$ 1mg/dL and Patient's global health (PaGH)  $\leq$ 1 (0-10 scale). When using this criterion for remission, it has been shown that one-third of patients with RA fail to reach remission solely because of PaGH (near-remission).(6) If the current treatment recommendations would be followed,(3) based on the Boolean remission definition a state of near-remission could lead to an adaptation of disease-modifying anti-rheumatic drugs (DMARDs) and potential overtreatment, although isolated PaGH elevation suggests needs that are not necessarily related to inflammation.(7) Hence, in such cases the remaining disease burden might not, or not only be mediated by disease activity. Several studies have shown a statistically significant correlation of PaGH with disease activity;(7,8) however, this correlation is absent in low levels of disease activity where PaGH is related to pain,

1  
2  
3 function and fatigue.(7–9) Unmet needs incorporated in the PaGH and their relative importance  
4  
5 should be uncovered when aiming to reduce the broader impact of RA.  
6  
7

8  
9 Recent research from our group has shown that adding pain, fatigue and physical function to the  
10  
11 components included in the traditional composite disease activity measures may provide  
12  
13 valuable additional information in evaluating the disease impact on the patient while keeping the  
14  
15 traditional components intact.(10) Overall, three factors or components were identified: a  
16  
17 patient-reported (PRF), clinical (CF) and laboratory (LF) factor. The patient-reported factor  
18  
19 consists of PaGH, pain, fatigue and physical function (HAQ): four self-reported measures that add  
20  
21 a separate patient-experienced aspect of evaluating the disease burden. The clinical factor  
22  
23 contains three variables: the physician's global health assessment (PhGH), swollen and tender  
24  
25 joint counts, all of which are common clinical measures. The laboratory factor comprises only  
26  
27 two laboratory measures: CRP and ESR. CF and LF scores have long been part of measuring  
28  
29 disease activity, while patient-reported factor is a novel addition. The three factors have also  
30  
31 been replicated in a patient sample with established RA.(11) Based on these results and data from  
32  
33 the CareRA trial(12), this paper aims to explore the potential benefit of evaluating these factor  
34  
35 scores and their patterns over time to better understand the disease burden, both from the  
36  
37 clinical and the patient's perspective. For this reason, we will plot the evolution of the three  
38  
39 factors in the CareRA trial and take their differences under the loop with a new indicator called  
40  
41 the discordance score, which allows us to study discorance between the traditional disease  
42  
43 activity measures and patient-reported outcomes. We will attempt to predict from baseline the  
44  
45 patient-reported, clinical and laboratory factors and discordance scores both later scores and  
46  
47 QoL outcomes. Moreover, by comparing patients achieving sustained (week 16 to 104) remission  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

(DAS28CRP<2.6) to those who do not achieve sustained remission, we illustrate how even the patients achieving sustained remission still report unmet needs such as pain and fatigue.(13)

## **PATIENTS AND METHODS**

CareRA was a 2-year open-label investigator-initiated pragmatic superiority trial (EudraCT number: 2008-007225-39, Clinical trials NCT01172639) conducted in 13 Flemish rheumatology centres.

Patients with recently diagnosed RA ( $\leq 1$  year) were included and stratified into a high- or low-risk group based on classical factors of poor prognosis (erosions, rheumatoid factor (RF) and/or anti-citrullinated cyclic peptide (anti-CCP) positivity and baseline disease activity score in 28 joints with C-reactive protein (DAS28CRP)  $> 3.2$ ) and then randomised into four different treatment arms. High-risk patients were randomised to methotrexate (MTX) 15mg weekly with a step-down glucocorticoid (GC) scheme or to this combination together with either sulphasalazine or leflunomide. Low-risk patients were randomised to a tight step-up treatment starting with MTX monotherapy without GC or to MTX weekly with step-down GCs. Overall, around 70% of the CareRA participants achieved a status of good disease control after 2 years (DAS28CRP  $< 2.6$ ) with a treat-to-target approach.(12)

### *Clinical outcomes*

Patients were assessed at screening, baseline and further at week 8, 16, 28, 40, 52, 65, 78, 91 and 104. Optional visits, if clinically required, could be performed. An electronic case report form was filled out and routinely monitored. Clinical, patient and laboratory parameters were collected at every visit: swollen (SJC28) and tender joint (TJC28) count in 28 joints, patient's global

1  
2  
3 health assessment (PaGH), physician's global health assessments (PhGH), C-reactive protein  
4 (CRP) or erythrocyte sedimentation rate (ESR), health assessment questionnaire (HAQ), pain and  
5  
6 fatigue each on a visual analogue scale (VAS) of 0-100. Overall QoL was captured with the Short  
7  
8 Form 36 (SF-36) and RA-specific QoL with the RAQoL questionnaire at baseline, week 16, 52 and  
9  
10 104. The SF-36 was standardised in 1990 as a self-report measure of functional health and well-  
11  
12 being. The SF-36 consists of eight scales: physical functioning (10 items), role-physical (4 items),  
13  
14 bodily pain (2 items), general health (5 items), vitality (4 items), social functioning (2 items), role-  
15  
16 emotional (3 items), mental health (5 items), and a final item, termed self-reported health  
17  
18 transition. To score the SF-36, scales are standardised with a scoring algorithm to obtain a score  
19  
20 ranging from 0 to 100.(14) Higher scores indicate better health status. The RAQoL contains 30  
21  
22 yes/no questions regarding specific activities of daily living and quality of life. Each positive  
23  
24 response is one point, a total sum is calculated giving a scale of 0-30.(15) Higher scores indicate  
25  
26 worse health status. Self-efficacy was measured by the 2-sub-scale version of the Arthritis Self-  
27  
28 Efficacy Scale (ASES) at week 52 and week 104.(16) The subscales for pain (PSE) and other  
29  
30 symptoms (OSE) measure the patient's perceived confidence in their ability to control arthritis  
31  
32 pain and to control symptoms of arthritis other than pain, respectively, with other means than  
33  
34 medication. PSE and OSE are scored separately, each subscale ranges from 1 to 10 ("very  
35  
36 uncertain" to "very certain"). The total ASES score (PSE+OSE) thus ranges from 2 to 20, with  
37  
38 higher scores indicating stronger self-efficacy beliefs.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

### 50 *Statistical analyses*

51  
52  
53 All randomised patients who had taken at least one medication dose, were considered for the  
54  
55 intention to treat (ITT) analysis. Missing data were assumed to be missing at random and were  
56  
57  
58  
59  
60

1  
2  
3 imputed with multiple imputation (classification and regression trees, n=100) by chained  
4  
5 equations.(17) Patient-reported questionnaire data (RAQoL, ASES, and SF-36) were first handled  
6  
7 as outlined in the individual questionnaire manuals. Missingness in clinical variables used to  
8  
9 estimate the factor scores, disease activity per time point, and questionnaire scores were  
10  
11 imputed. Besides the incomplete variables, treatment strategy, centre of recruitment, age,  
12  
13 gender, RF, anti-CCP, erosions at baseline, and trial completion were included as predictors in  
14  
15 the matrix. Each imputed dataset was analysed separately. Results of the 100 analyses were  
16  
17 pooled using Rubin's rules.(18). As described previously by Pazmino et al. (10), three factors were  
18  
19 identified using exploratory factor analysis on nine variables: Patient-Reported (PRF), Clinical  
20  
21 (CF), and Laboratory (LF) factor. Factor loadings, which represent how strongly a variable relates  
22  
23 to its factor, from the exploratory factor analyses (EFAs) were used as weights. The individual  
24  
25 variables were normalised to a 0-1 scale considering clinically feasible minimum and maximum.  
26  
27 Afterwards, the normalised (n.) variables were weighted -multiplied by the factor loadings- and  
28  
29 summed up as follows, to calculate the different factor scores:

$$PRF = (0.90 * n.fatigue) + (0.87 * n.PaGH) + (0.86 * n.pain) + (0.57 * n.HAQ)$$

$$CF = (0.92 * n.SJC28) + (0.89 * n.TJC28) + (0.76 * PhGH)$$

$$LF = (0.87 * n.CRP) + (0.78 * n.ESR)$$

30  
31  
32 Because the number of variables was different for each factor, the patient-reported, clinical and  
33  
34 laboratory factor scores were re-scaled to 0-1 (higher values suggest more health impact) for  
35  
36 comparisons. Thus, for each patient three factor scores per visit were obtained.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Furthermore, a discordance score (DS) for the PRF and CF/LF factor scores was calculated by  
4  
5 subtracting the mean of the other two factor scores from the PRF score:  
6  
7

$$DS = PRF - \left( \frac{CF + LF}{2} \right)$$

8  
9  
10  
11  
12  
13 The higher the score, the higher the patient-experienced impact not addressed by traditional  
14  
15 measures of disease activity. The DS goes from -1 to 1. Correlations between all three factor  
16  
17 scores and discordance scores per timepoint were calculated to assess the strength of the  
18  
19 relationship of the factor and discordance scores at different time points. Due to the skewed  
20  
21 distribution of the factor scores, Spearman correlations were used.  
22  
23  
24  
25

26 Furthermore, the percentage (%) of improvement from baseline to week 104 and the area-under-  
27  
28 the-curve (AUC) across time points were calculated per score. Differences in % improvement and  
29  
30 AUC were compared between patients not achieving and achieving early and sustained (week 16  
31  
32 to week 104) disease activity score remission (DAS28CRP <2.6) with ANOVA. Bonferroni  
33  
34 correction was used for multiple testing. We chose to look at patients achieving early and  
35  
36 sustained remission as a surrogate for “good responders” in whom we expected disease burden  
37  
38 to be less pronounced.(13,19) To find a clinically meaningful cut-off for the discordance score to  
39  
40 serve as an alarm system for unmet patient needs, we based ourselves on the SF-36. Receiver  
41  
42 Operator Characteristics (ROC) Curves were fitted for the discordance score to be able to classify  
43  
44 patients into good/poor health status based on SF-36. Without referring to norms, anytime a  
45  
46 scale score is below 50, health status is below average.(14) Logistic regression was fitted to  
47  
48 predict sustained remission based on factor and discordance scores at earlier time points with  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 and without adjustment for age and sex. Linear regressions to predict RA-QoL at week 52 and  
4  
5  
6 104 based on the factor scores was also employed.

7  
8  
9 All analyses were performed with R V.4.1.2.

### 10 11 *Ethics Approval*

12  
13  
14 The study was approved by the leading Ethics Committee of the University Hospitals Leuven after  
15  
16 consulting the medical ethics committee of each participating centre (ref s51411), and all study  
17  
18 participants gave their written informed consent before inclusion. Patient consent for publication  
19  
20 was not required.  
21  
22  
23  
24  
25  
26

## 27 **RESULTS**

28  
29 Patients with early RA (n=379) were included with a mean (SD) age of 53.9 (13.0), 77% positive  
30  
31 to RF or anti-CCP and 69% women (Table 1). In total, 289 were stratified to high risk and 90 to  
32  
33 low risk. Good retention rates of 85% were observed overall. Missingness in the clinical variables  
34  
35 over two years ranged from 0.3% to 39% per different time point and was 19% overall.  
36  
37  
38

39  
40 The patient-reported, clinical and laboratory factor scores improved rapidly over the first 8 weeks  
41  
42 (Figure 1a). From baseline to week 104 the scores improved 41%, 78% and 10% for the patient-  
43  
44 reported, clinical and laboratory factor scores respectively in the entire population (n=379), 57%,  
45  
46 90% and 27% in patients achieving sustained remission (n=122), and 32%, 77% and 9% in patients  
47  
48 not achieving sustained remission (n=257). After correction for multiple testing, there was a  
49  
50 statistically significant difference in the percentage of improvement from baseline to week 104  
51  
52 of CF ( $p<0.001$ ) between patients in sustained remission or not, but not in the improvement of  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 PRF ( $p=0.13$ ) or LF ( $p=0.36$ ) (Figure 1b). Figure 1 also indicates higher values of PRF scores at all  
4  
5 times, while CF and LF scores are rather similar, which illustrates the rationale for using the  
6  
7 discordance score. Further detailed information can be found in Supplementary Table S1,  
8  
9 available at *Rheumatology* online.  
10  
11

12  
13 Patients in the CareRA trial had an AUC of 27.4, 7.9 and 6.4 for PRF, CF, LF scores respectively in  
14  
15 the overall population. Those who achieved sustained remission had an AUC of 15.6, 3.4 and 4.8  
16  
17 for the patient-reported, clinical and laboratory factor scores respectively, compared to 33.2,  
18  
19 10.1, and 7.2 in participants not achieving sustained remission ( $p<0.001$  for all AUCs, between  
20  
21 patients in sustained remission or not).  
22  
23

24  
25 Supplementary Figure S1 (available at *Rheumatology* online) shows the Spearman correlations of  
26  
27 all three factor scores and their discordance scores at every time point. The correlations indicate  
28  
29 a strong relationship between the discordance scores at an early stage and both factor scores  
30  
31 and the discordance score at a later time point.  
32  
33

34  
35 Furthermore, both the patient-reported factor and the discordance score were predictive of  
36  
37 sustained remission from as early as baseline (Table 2) even after correcting for age, gender and  
38  
39 treatment group. The odds ratio in the multivariate model for the patient-reported factor score  
40  
41 lower than 1, implying that higher values in the PRF score were associated with a lower  
42  
43 probability of achieving sustained remission.  
44  
45

46  
47 Additionally, the discordance score proved to be predictive of RAQoL scores and self-efficacy  
48  
49 (ASES) both at week 52 and week 104 (Table 3) indicating the efficacy of the predictive value of  
50  
51 the DS for an unrelated outcome measure.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 For determining thresholds for the discordance score to classify patients into good/poor health  
4 status based on SF-36 (SF-36 score above/below 50), an exploratory ROC curve analysis was  
5 performed. The area-under-the-curve for every time point was approximately 0.80. Different cut-  
6 offs are needed depending on the time point in the evolution of the disease, one for baseline  
7 (right before treatment has started) which was estimated at 0.23 and another for when  
8 treatment has taken effect (week 16, 52, 104) of around 0.10 to 0.15 (Figure 2).  
9  
10  
11  
12  
13  
14  
15  
16  
17

## 18 **DISCUSSION**

19  
20  
21 In this paper, we presented the discordance score as a novel indicator of discrepancy between  
22 patient-reported outcomes and more traditional measures of disease activity. We previously  
23 identified three factors representing the broader impact of RA using exploratory factor analysis:  
24 a patient-reported factor (patient's health assessment, pain, fatigue and HAQ), a clinical factor  
25 (physician's health assessment, tender/swollen joint count), and a laboratory factor (ESR and  
26 CRP). The PRF, CF and LF scores improved rapidly over time in a treat-to-target setting in patients  
27 with early RA participating in the CareRA trial. However, overall, patient-reported impact (PRF)  
28 seemed not to improve to the same extent. In fact, PRF remained in all time points higher than  
29 either CF or LF scores, despite being normalised to the same scale. Furthermore, the difference  
30 seems to be constant over time after week 8. This means that assessment of the discordance  
31 between PRF scores and the other factor scores may (from very early in the treatment process)  
32 be used as a **warning system** or perhaps even further developed as a **clinical decision support**  
33 **tool** for the clinician, since it predicts future patient-reported impact. Even more importantly, it  
34 could detect at an earlier stage, unmet needs even in patients "under control", which is clinically  
35 relevant considering that one in five persistent treatment responders from CareRA reported  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 unmet needs after 1 year, such as remaining pain and fatigue.(13) The fact that two cut-offs are  
4  
5 needed for the discordance score seems to indicate that there is a different way of evaluating  
6  
7 additional patients' needs not directly explained by disease activity after recently being  
8  
9 diagnosed (baseline) versus when treatment has been started. However, replicating these results  
10  
11 in independent samples and establishing external validity is needed. At baseline, it is likely that  
12  
13 quite an important part of this need is related to unmeasured (CF/LF) but experienced (PRF)  
14  
15 disease activity, while this explanation becomes less plausible during further treatment.  
16  
17  
18

19  
20 Moreover, the a better (lower) PRF score also has a predictive value in forecasting if a patient will  
21  
22 be achieving sustained remission. These findings may be somewhat limited since the analyses  
23  
24 were exploratory and not powered for assessing prediction models based on the factor and  
25  
26 discordance scores. Hence, there could be an effect of the LF which could not be captured due  
27  
28 to too low a sample size. The probability of achieving a state of disease control decreases from  
29  
30 baseline onwards for every point increase in the PRF score and the negative predictive value of  
31  
32 the PRF score becomes even more important by week 16, highlighting again the importance of  
33  
34 early disease control, also for global disease impact. Keeping an open mind to the alternative that  
35  
36 complementary interventions besides DMARDs could help mitigate the “persisting effect of  
37  
38 disease” is crucial. This is an important issue in the current(20,21) and future research. Studies in  
39  
40 other patient cohorts than the one the scores were developed in are needed for future validation  
41  
42 of these factor and discordance scores and their possible cut-offs for further clinical use.  
43  
44 Additional qualitative studies are also needed to understand what is behind this discordance  
45  
46 between patient-reported outcomes and clinical variables.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Rapid and persistent disease control as well as baseline psychosocial variables, and not so much  
4 treatment choice, have been associated with favourable patient-reported health and illness  
5 perceptions after 1 year in CareRA. (19) Moreover, treatment response along with patient-  
6 reported outcomes have been proven to be early determinants of long-term self-efficacy in an  
7 early RA.(22) The early, intensive, treat-to-target approach(3) definitely has its benefits with  
8 snowballing consequences that can go further than controlling disease activity.(23) However,  
9 there might be space for broadening the target currently used.(3)

## 20 21 **CONCLUSION**

22 Patients' unmet needs in terms of pain, fatigue, functionality and overall well-being should be  
23 given more attention during follow-up, even in individuals achieving sustained remission. Looking  
24 at the discordance between the patient-reported factor score and the clinical and laboratory  
25 factor scores does provide further insights into these needs that cannot be directly explained by  
26 standard disease activity parameters. These needs could also represent a target for additional  
27 types of care, allowing to broaden the future scope of the treat-to-target principle to  
28 multidisciplinary interventions in addition to, and sometimes as an alternative for  
29 pharmacological treatment adaptations.

## 42 43 **Acknowledgements**

44 We would like to show our gratitude to all participating patients, as well as to the investigators  
45 and medical staff at all sites. We appreciate the time invested.

## 49 50 **Contributors**

51 PV, RW, AB, SP, and AL made substantial contributions to the conception or design of the study.  
52 SP and AL performed the statistical analysis. The manuscript was written by SP, AL, PV, RW, and  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 AB and subsequently revised critically by all the remaining co-authors. All authors were involved  
4  
5 in data interpretation and approved the final version to be submitted for publication.  
6  
7

8 **Patient involvement:** The pragmatic CareRA protocol was strongly inspired by daily interactions  
9  
10 of the investigators with RA patients in daily clinical practice. Patients were not formally involved  
11  
12 in setting the research question or the outcome measures, nor were they invited to comment on  
13  
14 study design or the interpretation of the results of this manuscript. However, results of this  
15  
16 research will be disseminated to study participants, all stakeholders and the general public in  
17  
18 collaboration with patient organisations and the Belgian patient partners program (trained  
19  
20 patients who educate physicians, medical students and other health care professionals in  
21  
22 collaboration with a rheumatologist).  
23  
24  
25  
26  
27

28 **Funding:** The CareRA trial (EudraCT number: 2008-007225-39) was funded by a Flemish  
29  
30 governmental grant (Agency for Innovation by Science and Technology [IWT]). Patrick  
31  
32 Verschueren holds the Pfizer chair for early rheumatoid arthritis management at the KU Leuven.  
33  
34

35 **Competing interests:** The authors have declared no conflicts of interest.  
36  
37

38 **Data availability statement:** The authors commit to making the relevant anonymised patient  
39  
40 data available for a specified purpose approved by the institution and the principal investigator  
41  
42 of the CareRA study and with a signed data access agreement.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. In: *The Lancet*. 2010. p. 1094–1108. [https://doi.org/10.1016/S0140-6736\(10\)60826-4](https://doi.org/10.1016/S0140-6736(10)60826-4).
2. Van Riel PLCM. *The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28)*. *Clin Exp Rheumatol*. 2014.
3. Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Annals of the Rheumatic Diseases*. 2020;79: 685–699. <https://doi.org/10.1136/annrheumdis-2019-216655>.
4. Smolen JS, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: Recommendations of an international task force. *Annals of the Rheumatic Diseases*. 2010;69(4): 631–637. <https://doi.org/10.1136/ard.2009.123919>.
5. Ferreira RJ, Landewé RB, da Silva JA. Definition of Treatment Targets in Rheumatoid Arthritis: Is It Time for Reappraisal? *The Journal of Rheumatology*. 2021; <https://doi.org/10.3899/jrheum.210050>.
6. Ferreira RJ de O, Dougados M, Kirwan JR, Duarte C, de Wit M, Soubrier M, et al. Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: An analysis of 1588 patients. *Rheumatology (United Kingdom)*. 2017;56(9): 1573–1578. <https://doi.org/10.1093/rheumatology/kex211>.
7. Ferreira RJO, Carvalho PD, Ndosí M, Duarte C, Chopra A, Murphy E, et al. Impact of Patient's Global Assessment on Achieving Remission in Patients With Rheumatoid Arthritis: A Multinational Study Using the METEOR Database. *Arthritis Care and Research*. 2019;71(10): 1317–1325. <https://doi.org/10.1002/acr.23866>.
8. Ferreira RJO, Duarte C, Ndosí M, de Wit M, Gossec L, da Silva JAP. Suppressing Inflammation in Rheumatoid Arthritis: Does Patient Global Assessment Blur the Target? A Practice-Based Call for a Paradigm Change. *Arthritis Care and Research*. 2018;70(3): 369–378. <https://doi.org/10.1002/acr.23284>.
9. Radner H, Yoshida K, Tedeschi S, Studenic P, Frits M, Iannaccone C, et al. Different Rating of Global Rheumatoid Arthritis Disease Activity in Rheumatoid Arthritis Patients With Multiple Morbidities. *Arthritis and Rheumatology*. 2017;69(4): 720–727. <https://doi.org/10.1002/art.39988>.
10. Pazmino S, Lovik A, Boonen A, de Cock D, Stouten V, Joly J, et al. Does Including Pain, Fatigue, and Physical Function When Assessing Patients with Early Rheumatoid Arthritis Provide a Comprehensive Picture of Disease Burden? *The Journal of Rheumatology*. 2020;49(1). <https://doi.org/10.3899/jrheum.200758>.
11. Pazmino S, Lovik A, Westhovens R, Verschueren P. Evaluation of Disease Burden by (Separate) Patient-reported, Clinical, and Laboratory Factor Scores in Patients With Established Rheumatoid Arthritis: A Factor Analysis Replication. *The Journal of Rheumatology*. 2022; jrheum.210871. <https://doi.org/10.3899/JRHEUM.210871>.
12. Stouten V, Westhovens RR, Pazmino S, De Cock D, Van Der Elst K, Joly J, et al. Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-

- 1  
2  
3 year results of CareRA. *Rheumatology (Oxford, England)*. 2019;  
4 <https://doi.org/10.1093/rheumatology/kez213>.  
5
- 6 13. Van Der Elst K, Verschueren P, De Cock D, De Groef A, Stouten V, Pazmino S, et al. One in five  
7 patients with rapidly and persistently controlled early rheumatoid arthritis report poor well-being  
8 after 1 year of treatment. *RMD Open*. 2020;6(1). [https://doi.org/10.1136/rmdopen-2019-](https://doi.org/10.1136/rmdopen-2019-001146)  
9 001146.  
10
- 11 14. Ware J. . SF-36 Health Survey Update. *Spine*. 2000;25(24): 3130–3139.  
12
- 13 15. Whalley D, Mckenna SP, de Jong Z, van der Heijde D. *Quality of life in Rheumatoid Arthritis*.  
14 *British Journal of Rheumatology*. 1997.  
15
- 16 16. Barlow JH, Williams B, Wright CC. The reliability and validity of the arthritis self-efficacy scale in a  
17 UK context. <http://dx.doi.org/10.1080/13548509708400556>. 2007;2(1): 3–17.  
18 <https://doi.org/10.1080/13548509708400556>.  
19
- 20 17. Burgette LF, Reiter JP. Multiple imputation for missing data via sequential regression trees.  
21 *American Journal of Epidemiology*. 2010;172(9): 1070–1076.  
22 <https://doi.org/10.1093/aje/kwq260>.  
23
- 24 18. Rubin DB, Schenker N. Multiple imputation for interval estimation from simple random samples  
25 with ignorable nonresponse. *Journal of the American Statistical Association*. 1986;81(394): 366–  
26 374. <https://doi.org/10.1080/01621459.1986.10478280>.  
27
- 28 19. Van der Elst K, Verschueren P, Stouten V, Pazmino S, De Groef A, De Cock D, et al. Patient  
29 reported outcome data from the Care in Early Rheumatoid Arthritis trial: Opportunities for  
30 broadening the scope of treating to target. *Arthritis Care & Research*. 2019;  
31 <https://doi.org/10.1002/acr.23900>.  
32
- 33 20. Doumen M, Westhovens R, Vandeputte M, Melder R van, Elst K van der, Pazmino S, et al. The  
34 perception of stakeholders on the applicability of nurse-led clinics in the management of  
35 rheumatoid arthritis. *Rheumatology Advances in Practice*. 2021;5(Suppl 2): ii45.  
36 <https://doi.org/10.1093/RAP/RKAB052>.  
37
- 38 21. Doumen M, Westhovens R, Pazmino S, Bertrand D, Stouten V, Neys C, et al. The ideal mHealth-  
39 application for rheumatoid arthritis: qualitative findings from stakeholder focus groups. *BMC*  
40 *Musculoskeletal Disorders*. 2021;22(1). <https://doi.org/10.1186/S12891-021-04624-8>.  
41
- 42 22. Doumen M, de Cock D, Pazmino S, Bertrand D, Joly J, Westhovens R, et al. Treatment response  
43 and several patient-reported outcomes are early determinants of future self-efficacy in  
44 rheumatoid arthritis. *Arthritis research & therapy*. 2021;23(1): 269.  
45 <https://doi.org/10.1186/S13075-021-02651-3>.  
46
- 47 23. Schoemaker CG, de Wit MP. Treat to target from the patient perspective is bowling for a perfect  
48 strike. *Arthritis & Rheumatology*. 2020; art.41461. <https://doi.org/10.1002/art.41461>.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Figure 1: Factor-scores over time for a. the entire population and b. per sustained remission.  
4  
5

6  
7 Figure 2: Patient classification into good/poor health status (based on SF-36) using the  
8 discordance score.  
9

10 AUC = area under the curve  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1:** Demographic and clinical characteristics at baseline per sustained remission achievement (DAS28CRP <2.6 from week 16 to 104)

	CareRA population n=379	Not sustained remission n=252	Sustained remission n=127
<b>Demographic variables</b>			
Age, years	52 (10)	52 (11)	51 (11)
Women, n (%)	262 (69)	174 (69)	88(69)
Smokers, n smoked ever (%)	209 (55)	143 (57)	66 (52)
Current work n (%)	193 (51)	125 (50)	68 (54)
<b>Clinical variables</b>			
Body mass index, kg/m <sup>2</sup>	26 (5)	27(4)	26 (4)
Symptom duration, weeks; median (IQR)	20 (12-36)	21 (13-42)	17 (10-29)
RF positive, n (%)	252 (67)	169 (67)	83 (65)
Anti-CCP positive, n (%)	249 (66)	169 (67)	80 (63)
Erosive disease, n (%)	97 (26)	65 (26)	32 (25)
DAS28-CRP	4.50 (1.28)	4.69 (1.25)	4.10 (1.25)
CRP mg/L	9.94 (15.31)	11.56 (26.33)	6.72 (15.07)
SJC28 (0-28)	7 (6)	8 (6)	6 (5)
TJC28 (0-28)	9 (7)	10 (6)	7 (6)
PhGH, mm (0-100)	52 (22)	54 (19)	48 (19)
PaGH, mm (0-100)	55 (27)	58 (23)	49 (24)
Pain, mm (0-100)	56 (24)	60 (24)	49 (24)
Fatigue, mm (0-100)	48 (28)	52 (23)	40 (24)
HAQ score (0-3)	1.03 (0.71)	1.14 (0.71)	0.81 (0.66)
RAQoL (0-30)	11 (8)	13 (7)	9 (7)

Data are presented as mean and standard deviation (SD) unless otherwise specified.

Symptom duration= number of weeks between the onset of symptoms and the start of treatment; RF= Rheumatoid factor; Anti-CCP= Anti cyclic citrullinated protein; DAS28= Disease activity score on 28 joints; CRP= C-reactive protein; SJC28= swollen joint count in 28 joints; TJC28= tender joint count in 28 joints; PhGH= physician's global health assessment; PaGH= patient's global health assessment; HAQ= Health Assessment Questionnaire; RAQoL = rheumatoid arthritis quality of life questionnaire.

**Table 2:** Prediction of sustained remission (DAS28CRP<2.6 from week 16 to 104) using previous DS.

Logistic regression predicting sustained remission based on	Baseline		Week 8		Week 16	
	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value
<b>Multivariate models adjusted for gender, age, and treatment group</b>						
<b>Patient factor</b>	0.64 (0.48-0.85)	0.002	0.50 (0.37-0.68)	<0.0001	0.42 (0.32-0.56)	<0.0001
<b>Clinical factor</b>	0.79 (0.57-1.12)	0.18	0.46 (0.28-0.76)	0.003	0.46 (0.26-0.83)	0.01
<b>Laboratory factor</b>	0.96 (0.61-1.50)	0.85	0.75 (0.32-1.77)	0.51	0.57 (0.25-1.29)	0.18
<b>Discordance score</b>	0.67 (0.50-0.89)	0.006	0.42 (0.31-0.57)	<0.0001	0.38 (0.28-0.50)	<0.0001
OR= odds ratio, CI= confidence interval						

**Table 3:** Prediction of RA-related quality of life and self-efficacy based on previous discordance score.

Linear regression predicting RA-QoL at		Based on discordance score at week 16, corrected for age, gender, treatment group, and sustained remission.			
		Intercept (SE)	Beta (SE) for DS	p-value for DS	Adjusted R square (95% CI)
<b>RAQoL (0-30)</b>					
<b>Week 52</b>		3.15 (1.49)	20.76 (1.78)	<0.0001	0.29 (0.21-0.37)
<b>Week 104</b>		2.17 (1.47)	21.38 (1.74)	<0.0001	0.31 (0.23-0.40)
<b>ASES</b>					
<b>Week 52</b>					
<b>Total (2-20)</b>		7.90 (0.41)	-3.48 (0.53)	<0.0001	0.13 (0.06-0.21)
<b>Pain (1-10)</b>		3.94 (0.26)	-1.59 (0.34)	<0.0001	0.07 (0.02-0.14)
<b>Other symptoms (1-10)</b>		3.97 (0.23)	-1.88 (0.28)	<0.0001	0.14 (0.07-0.23)
<b>Week 104</b>					
<b>Total (2-20)</b>		7.50 (0.43)	-3.81 (0.50)	<0.0001	0.17 (0.10-0.25)
<b>Pain (1-10)</b>		3.59 (0.28)	-1.88 (0.33)	<0.0001	0.11 (0.05-0.19)
<b>Other symptoms (1-10)</b>		3.92 (0.24)	-1.94 (0.28)	<0.0001	0.16 (0.09-0.25)

SE= standard error, CI= confidence interval, DS= discordance score, RAQoL= rheumatoid arthritis quality of life questionnaire, ASES= Arthritis Self-Efficacy Scale




Figure 1

635x762mm (118 x 118 DPI)




Figure 2

381x317mm (236 x 236 DPI)